Cipla’s arm acquires prescription drug ZEMDRI from Achaogen

25 Jul 2019 Evaluate

Cipla’s wholly-owned subsidiary -- Cipla USA Inc. has acquired the prescription drug ZEMDRI (Plazomicin) from Achaogen Inc. in a Chapter 11, US Bankruptcy Code auction of Achaogen’s assets. Cipla USA has acquired worldwide rights of ZEMDRI (excluding Greater China) with its allied assets and limited liabilities.

ZEMDRI is a once-daily novel intravenous (IV) aminoglycoside for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, in adults who are unresponsive to currently available treatment options.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1509.40 9.30 (0.62%)
02-Jan-2026 12:32 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1726.00
Dr. Reddys Lab 1249.00
Cipla 1509.40
Zydus Lifesciences 916.30
Lupin 2099.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×